Asian Pacific Journal of Cancer Prevention

  • 제13권11호
  • /
  • Pages.5721-5724
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

  • Gan, Yi (Department of General Surgery, 3rd Xiang-Ya Hospital of Central South University) ;
  • Li, Xiao-Rong (Department of General Surgery, 3rd Xiang-Ya Hospital of Central South University) ;
  • Chen, Dao-Jin (Department of General Surgery, 3rd Xiang-Ya Hospital of Central South University) ;
  • Wu, Jun-Hui (Department of General Surgery, 3rd Xiang-Ya Hospital of Central South University)
  • 발행 : 2012.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We conducted this study to detect associations between XRCC1 Arg399Gln and XPD Lys751Gln genotypes and survival of colorectal cancer patients treated with 5-FU/oxalipatin chemotherapy. We included 289 Chinese patients with advanced colorectal cancer, who had received 5-FU/oxalipatin chemotherapy as first-line treatment from January 2005 to January 2007. All patients were followed up till Nov. 2011. Genotyping for XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms was based upon duplex polymerase-chain-reaction with the PCR-RFLP method. In our study, we found the XRCC1 399 Gln/Gln genotype to confer significantly higher rates of response to chemotherapy when compared to the Arg/Arg genotype [OR (95% CI)= 2.56(1.57-2.55)]. patients with the XPD 751 Gln/Gln genotype had significantly higher rates of response to chemotherapy [OR (95% CI)= 1.54(0.87-2.65)] and those with the XRCC1 399 Gln/Gln genotype had a longer average survival time and significantly lower risk of death than did those with the Arg/Arg genotype [HR (95% CI)= 0.66(0.36-0.95)]. Similarly, those carrying the XPD 751Gln/Gln genotype had 0.51-fold the risk of death of those with XPD 751Lys/Lys [HR (95% CI)= 0.51(0.33 -0.94)]. In conclusion, it is suggested that the XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms should be routinely assessed to determine colorectal patients who are more likely to benefit from 5-FU/oxalipatin chemotherapy.

키워드

참고문헌

  1. Chang-Claude J, Popanda O, Tan XL, et al (2005). Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res, 11, 4802-9. https://doi.org/10.1158/1078-0432.CCR-04-2657
  2. Chang PM, Tzeng CH, Chen PM, et al (2009). ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and clinical outcome to FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci, 100, 278-83. https://doi.org/10.1111/j.1349-7006.2008.01031.x
  3. Fard-Esfahani P, Fard-Esfahani A, Fayaz S (2011). Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J, 15, 73-8.
  4. Grimminger PP, Brabender J, Warnecke-Eberz U, et al (2010). VallbohmerXRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res, 164, e61-6. https://doi.org/10.1016/j.jss.2010.08.002
  5. Handra-Luca A, Hernandez J, Mountzios G, et al (2007). Excision repair cross complementation group1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res, 13, 3855-9. https://doi.org/10.1158/1078-0432.CCR-07-0252
  6. Hoeijmakers JH, Egly JM, Vermeulen W (1996). TFIIH: a key component in multiple DNA transaction. Curr Opin Gene Dev, 6, 26-33. https://doi.org/10.1016/S0959-437X(96)90006-4
  7. International Agency for Research on Cancer (2008). Colorectal Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr.
  8. Lai JI, Tzeng CH, Chen PM, et al (2009). Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 100, 1261-6. https://doi.org/10.1111/j.1349-7006.2009.01186.x
  9. Lamas MJ, Duran G, Balboa E, et al (2011). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12, 433-42. https://doi.org/10.2217/pgs.10.196
  10. Lamas MJ, Duran G, Gomez A, et al (2012). D.X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys, 82, 138-44 https://doi.org/10.1016/j.ijrobp.2010.09.053
  11. Lunn RM, Langlois RG, Hsieh LL, et al (1999). XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res, 59, 2557-61.
  12. Lv H, Li Q, Qiu W, et al (2012). Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer. Pathol Oncol Res, 18, 1009-14. https://doi.org/10.1007/s12253-012-9536-6
  13. Manuguerra M, Saletta F, Karagas MR, et al (2006). XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol, 164, 297-302. https://doi.org/10.1093/aje/kwj189
  14. McWilliams RR, Bamlet WR, Cunningham JM, et al (2008). Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res, 68, 4928-35. https://doi.org/10.1158/0008-5472.CAN-07-5539
  15. Mohrenweiser HW, Jones IM (1998). Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res, 400, 15-24. https://doi.org/10.1016/S0027-5107(98)00059-1
  16. Park DJ, Stoehlmacher J, Zhang W, et al (2001). Xeroderma pgmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res, 61, 8654-9.
  17. Parshad R, Tarone RE, Price FM, et al (1993). Cytogenetic evidence for differences in DNA incision activity in xeroderma pigmentosum group A, C and D cells after X-irradiation during G2 phase. Mutat Res, 294, 149-55. https://doi.org/10.1016/0921-8777(93)90023-A
  18. Raabe A, Derda K, Reuther S, et al (2012). Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol, 7, 65. https://doi.org/10.1186/1748-717X-7-65
  19. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998). Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol, 25, 4-12.
  20. Rzeszowska-Wolny J, Polanska J, Pietrowska M, et al (2005). Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res, 164, 132-40. https://doi.org/10.1667/RR3400
  21. Saldivar JS, Wu X, Follen M, Gershenson D (2007). Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol, 107, S56-71. https://doi.org/10.1016/j.ygyno.2007.07.043
  22. Schaeffer L, Moncollin V, Roy R, et al (1994). The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J, 13, 2388-92.
  23. Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer research, 58, 604-8.
  24. Shields PG, Harris CC (2000). Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol, 18, 2309-15. https://doi.org/10.1200/JCO.2000.18.11.2309
  25. Shore RE, Zeleniuch-Jacquotte A, Currie D, et al (2008). Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk. Int J Cancer, 122, 2101-5. https://doi.org/10.1002/ijc.23361
  26. Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5. https://doi.org/10.1038/365852a0
  27. Zhao Y, Deng X, Wang Z, et al (2012). Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev, 13, 665-9. https://doi.org/10.7314/APJCP.2012.13.2.665
  28. Zhou W, Gurubhagavatula S, Liu G et al (2004). Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 10, 4939-43. https://doi.org/10.1158/1078-0432.CCR-04-0247

피인용 문헌

  1. ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients vol.8, pp.9, 2013, https://doi.org/10.1371/journal.pone.0071994
  2. Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case–control study in northwest China vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1191-3
  3. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients vol.17, pp.7, 2016, https://doi.org/10.2217/pgs-2015-0017
  4. XPD–The Lynchpin of NER: Molecule, Gene, Polymorphisms, and Role in Colorectal Carcinogenesis vol.5, pp.2296-889X, 2018, https://doi.org/10.3389/fmolb.2018.00023